Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2001-05-18
2003-05-27
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S731000, C514S451000, C514S452000, C536S120000, C536S043000, C536S004100, C536S018600, C568S716000
Reexamination Certificate
active
06569906
ABSTRACT:
The present invention relates to a cosmetic or pharmaceutical composition for skin application, containing a compound capable of releasing a biologically active substance in contact with the skin through the action of an enzyme of the skin surface: glucocerebrosidase.
The expression “precursor of an active agent” is understood to mean a conjugated compound of an inactive molecule with a biologically active substance. A precursor of an active agent has no inherent biological activity (or has a low activity), and releases, once metabolized, said active substance in the stratum corneum. A “derivative of an active agent” is distinguishable from a “precursor of an active agent” in that it is endowed with an inherent biological activity.
The use of precursors of active agents in cosmetology is a common practice, in particular for enhancing the stability of the active agents in the compositions and/or for facilitating the penetration of the active agents into the epidermis.
Precursors of vitamins are widely used in this regard.
Indeed, vitamins are difficult to formulate because of their high instability to air and to heat.
Vitamin derivatives having a structure similar to the active molecule and whose stability would be improved were first proposed. These derivatives have nevertheless proved to have excessively low activities.
Precursors of vitamins, such as esters of fatty acids, esters of glycerides, phosphates or sulfates of vitamins, are preferred to them.
The fatty acid esters of an active agent, such as vitamin E palmitate (or alpha-tocopherol palmitate), have the advantage not only of stabilizing the active agent but also of enhancing the skin penetration of a water-soluble active agent by increasing its affinity for the lipophilic stratum corneum.
Patent application FR-2 715 565 describes a composition containing two precursors which release the same active agent according to two different kinetics through a synergetic mechanism. The precursors are chosen from phosphates, sulfates, palmitates, propionates, acetates, ferulates, ethers, amides and glycosidic derivatives of active agents.
The compositions given as examples contain two precursors of vitamin C: phosphated vitamin C and glucosylated vitamin C. These two precursors interact with two different enzymes, a phosphatase and a glucosidase, to release vitamin C in a synergetic manner.
Patent application EP-487 404 describes the use of a glucosylated precursor of vitamin C (or ascorbic acid) for preparing a dermatological composition which exerts a vitamin C activity in the body. This application describes in particular alpha-glucolsyl-L-ascorbic acids, which have no inherent activity and which are hydrolyzed to glucose and to L-ascorbic acid by a cutaneous enzyme.
Some glycosidic derivatives of active agents, which themselves have a biological activity, have already been described.
In the context of a study on tocopherols (EP-169 716), it has been demonstrated that the glucosylated derivatives of delta-tocopherol have an anti-allergic activity. Patent JP-60 56 994 describes the antioxidant activity of dl-alpha-tocopherylglucose, dl-alpha-tocopherylgalactose and d-delta-tocopherylgalactose. The activity of these glucosylated derivatives of tocopherol has nevertheless proved insufficient such that their use as a biologically active substance is of little interest.
The object of the present invention is to provide a composition for skin application which releases an active agent according to a kinetics such that the concentration of active agent in the epidermis remains greater than the biologically active concentration, but less than the pro-inflammatory concentration.
The applicant has indeed demonstrated that conventional cosmetic compositions containing an active agent such as vitamin E generate a pro-inflammatory effect. This pro-inflammatory effect is the consequence of a superactivity of the active agent at the concentration used. This is all the more problematic as the concentration used is necessary in order to observe the desired biological effects.
To avoid any excessive concentration of the active agent in the period following skin application of the composition, the applicant proposes using a precursor of an active agent which is capable of being hydrolyzed by an enzyme whose kinetics meets the two criteria set out above.
The applicant has demonstrated that glucocerebrosidase makes it possible to solve the problem posed.
It is known that the inhibition of glucocerebrosidase by topical treatment with bromo-condutirol-B-epoxide causes acute barrier function disruptions (Holleran W. M., Elias P. M., “Permeability barrier requirements regulate epidermal &bgr;-glucocerebrosidase”, J. Lipid. Res., 1994, 35, 905-912).
These results demonstrate that, on the one hand, this enzyme is accessible via the topical route and, on the other hand, that it plays an essential role in the equilibrium of the cutaneous system.
Furthermore, glucocerebrosidase exhibits a high activity in the stratum corneum: the natural substrates of this enzyme, glucocerebrosides, are hydrolyzed to ceramides which represent 40% by weight of the lipids in the stratum corneum (Lampe M. A., Williams M. L. and Elias P. M., “Human epidermal lipids: characterization and modulation during differentiation”, J. Lipid. Res., 24, 131-140).
The applicant has demonstrated, by clinical studies carried out on 22 patients, that the activity of glucocerebrosidase varies little as a function of the depth of the horny layer and varies little as a function of the individuals and of the season. Glucocerebrosidase is therefore a hydrolase with a high and constant activity.
The applicant has, in addition, demonstrated that the kinetics of glucocerebrosidase hydrolysis makes it possible to envisage the use of a precursor of an active agent which releases the active agent at a rate which is both sufficient to ensure its activity and moderate to avoid any intolerance due to an excessive concentration of the active agent.
Accordingly, the subject of the present invention is a cosmetic or pharmaceutical composition for skin application containing a compound capable of releasing a biologically active substance in contact with the skin through the action of a cutaneous enzyme, characterized in that the enzyme is glucocerebrosidase.
The expression “compound capable of releasing a biologically active substance” is understood to mean a compound having a structure similar to a natural substrate of said enzyme.
According to a preferred embodiment, the compound capable of releasing the biologically active substance is a conjugated compound of said substance with a carbohydrate such that:
said biologically active substance has a phenol residue in which the two carbons at the alpha position of the phenol functional group are unsubstituted, and
the chemical linkage between said biologically active substance and said carbohydrate is an ether functional group between the carbohydrate and the phenol functional group of the biologically active substance.
In order to facilitate the penetration of the precursor of an active agent into the stratum corneum, the biologically active substance advantageously exhibits a lipophilic character.
The carbohydrate is a C3-C6 monosaccharide such as glucose, mannose, galactose, preferably glucopyranose or one of its derivatives.
The biologically active substance may be a therapeutically active substance chosen from tioxolone, paracetamol, oxyphenylbutazone, isoxsuprine, etilefrine, p-pentyloxyphenol, delta-tocopherol, tocol and flavonoids.
The formula for the compounds listed is given below.
Paracetamol corresponds to p-acetamidophenol. In the formulae for tocol and delta-tocopherol, C
16
H
33
at the 2-position of the 3,4-dihydrobenzopyran is 4,8,12-trimethyltridecyl substituent.
The biologically active substance may have an action strictly at the level of the epidermis, in particular when it is chosen from tocol, delta-tocopherol, flavonoids (which are antioxidants) and tioxolone (which is an anti-seborrheic agent).
The biologically active substance may al
Perie Jean-Jacques
Redoules Daniel
Tarroux Roger
Barts Samuel
Khare Devesh
Pierre Fabre Dermo-Cosmetique
The Firm of Hueschen and Sage
LandOfFree
Composition containing a precursor capable of being... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition containing a precursor capable of being..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition containing a precursor capable of being... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3013062